Vaccination against high blood pressure

Current Pharmaceutical Design

Volumn 18, Issue 7, 2012, Pages 1005-1010

  Campbell, Duncan J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiotensin converting enzyme inhibitor; Angiotensin i; Angiotensin II; Angiotensin II type 1 receptor; Angiotensin receptor blocker; Immunization; Renin

Indexed keywords

ALUMINUM HYDROXIDE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; ENALAPRIL; KEYHOLE LIMPET HEMOCYANIN; RENIN;

ANTIBODY TITER; ARTICLE; BLOOD PRESSURE REGULATION; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; VACCINATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; VACCINATION;

EID: 84857131635     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799436511     Document Type: Article

References (55)

1. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25: 305-13.
2. Wong ND, Lopez VA, L'Italien G, Chen R, Kline SE, Franklin SS. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004. Arch Intern Med 2007; 167: 2431-6.
3. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. Journal of the American Medical Association 2002; 287: 1003-10.
4. World Health Organization. World Health Report 2002: reducing risks, promoting healthy life. Geneva: World Health Organization 2002.
5. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
6. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-35.
7. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New England Journal of Medicine 1991; 325: 293-302.
8. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New England Journal of Medicine 1992; 327: 685-691.
9. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
10. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-7.
11. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
12. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
13. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.
14. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22: 11-9.
15. Perreault S, Lamarre D, Blais L, et al. Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmacother 2005; 39: 1401-8.
16. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. Br Med J 2008; 336: 1114-7.
17. Michel JB, Guettier C, Reade R, Sayah S, Corvol P, Ménard J. Immunologic approaches to blockade of the renin-angiotensin system: A review. Am.Heart J 1989; 117: 756-67.
18. Michel JB, Galen FX, Guettier C, et al. Immunological approach to blockade of the renin-substrate reaction. J Hypertens Suppl 1989; 7: S63-70.
19. Michel JB. Renin-angiotensin vaccine: old story, new project 'efficacy versus safety'. Clin Sci (Lond) 2004; 107: 145-7.
20. Menard J. A vaccine for hypertension. J Hypertens 2007; 25: 41-6.
21. Brown MJ. Success and failure of vaccines against reninangiotensin system components. Nat Rev Cardiol 2009; 6: 639-47.
22. Gradman AH, Pinto R. Vaccination: a novel strategy for inhibiting the renin-angiotensin-aldosterone system. Curr Hypertens Rep 2008; 10: 473-9.
23. Campbell DJ. Angiotensin vaccination: what is the prospect of success? Curr Hypertens Rep 2009; 11: 63-8.
24. Campbell DJ, Duncan A-M, Kladis A, Harrap SB. Angiotensin peptides in spontaneously hypertensive and normotensive Donryu rats. Hypertension 1995; 25: 928-934.
25. Downham MR, Auton TR, Rosul A, et al. Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man. Br J Clin Pharmacol 2003; 56: 505-12.
26. Brown MJ, Coltart J, Gunewardena K, Ritter JM, Auton TR, Glover JF. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond) 2004; 107: 167-73.
27. Ambühl PM, Tissot AC, Fulurija A, et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 2007; 25: 63-72.
28. Tissot AC, Maurer P, Nussberger J, et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008; 371: 821-7.
29. Pandey R, Quan WY, Hong F, Jie SL. Vaccine for hypertension: modulating the renin-angiotensin system. Int J Cardiol 2009; 134: 160-8.
30. Brown MJ. Therapeutic potential of vaccines in the management of hypertension. Drugs 2008; 68: 2557-60.
31. Hong F, Quan WY, Pandey R, et al. A vaccine for hypertension based on peptide AngI-R: a pilot study. Int J Cardiol 2011; 148: 76-84.
32. Renner WA. Cytos Biotechnology updates on the development of the hypertension vaccine CYT006-AngQb. 2009; [cited 2011 October 14]. Available from: http://www.cytos.com/?id=138
33. Bachmann MF, Jennings GT. Therapeutic vaccines for chronic diseases: successes and technical challenges. Philos Trans R Soc Lond B Biol Sci 2011; 366: 2815-22.
34. Campbell DJ. The site of angiotensin production. Journal of Hypertension 1985; 3: 199-207.
35. Wiig H, Gyenge CC, Tenstad O. The interstitial distribution of macromolecules in rat tumours is influenced by the negatively charged matrix components. J Physiol 2005; 567: 557-67.
36. Admiraal PJJ, Derkx FHM, Danser AHJ, Pieterman H, Schalekamp MADH. Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension 1990; 15: 44-55.
37. Maillard MP, Wurzner G, Nussberger J, Centeno C, Burnier M, Brunner HR. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin. Pharmacol. Ther. 2002; 71: 68-76.
38. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002; 39: e1-e8.
39. Admiraal PJJ, Derkx FHM, Danser AHJ, Pieterman H, Schalekamp MADH. Intrarenal de novo production of angiotensin I in subjects with renal artery stenosis. Hypertension 1990; 16: 555-563.
40. Refetoff S. Inherited thyroxine-binding globulin abnormalities in man. Endocr Rev 1989; 10: 275-93.
41. Stockigt J. Assessment of thyroid function: towards an integrated laboratory-clinical approach. Clin Biochem Rev 2003; 24: 109-22.
42. Lacourciere Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators. Am J Hypertens 1999; 12: 1181-7.
43. Coca A, Calvo C, Garcia-Puig J, et al. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorizacion Ambulatoria Presion Arterial APROVEL). Clin Ther 2002; 24: 126-38.
44. Prichard BN, Jager BA, Luszick JH, et al. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild to moderate essential hypertension. Blood Press 2002; 11: 166-72.
45. Zhu F, Liao YH, Li LD, et al. Target organ protection from a novel angiotensin II receptor (AT1) vaccine ATR12181 in spontaneously hypertensive rats. Cell Mol Immunol 2006; 3: 107-14.
46. Ready T. Blood pressure vaccine shot down by safety concerns. Nat Med 2005; 11: 1262.
47. Bachmann MF, Nussberger J, Tissot AC, Jennings GT. Reply to 'Blood pressure vaccine shot down by safety concerns'. Nat Med 2006; 12: 270.
48. Samuelsson O, Herlitz H. Vaccination against high blood pressure: a new strategy. Lancet 2008; 371: 788-9.
49. Shechter Y, Maron R, Elias D, Cohen IR. Autoantibodies to insulin receptor spontaneously develop as anti-idiotypes in mice immunized with insulin. Science 1982; 216: 542-5.
50. Batarseh H, Thompson RA, Odugbesan O, Barnett AH. Insulin receptor antibodies in diabetes mellitus. Clin Exp Immunol 1988; 71: 85-90.
51. Couraud PO. Anti-angiotensin II anti-idiotypic antibodies bind to angiotensin II receptor. J Immunol 1987; 138: 1164-8.
52. Xia Y, Ramin SM, Kellems RE. Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia. Hypertension 2007; 50: 269-75.
53. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558-69.
54. Mooser V, Nussberger J, Juillerat L, et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. Journal of Cardiovascular Pharmacology 1990; 15: 276-282.
55. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403-19.